Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- Check5 days agoChange DetectedA new publication citation about the safety and efficacy of dupilumab in infants and young children with atopic dermatitis was added to the Publications section, and an older online-ahead-of-print citation for the same topic was removed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, indicating a minor update to the page rendering or metadata. No study details are changed.SummaryDifference0.0%

- Check28 days agoChange DetectedUpdated the Publications section to replace the 'Online ahead of print' citation with the final published Paediatr Drugs article (May 2026) on long-term safety and efficacy of dupilumab in young children, including its DOI. The prior April 2, 2026 'Online ahead of print' citation for the same article was removed.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page’s displayed site revision/version was updated from v3.5.2 to v3.5.3, reflecting a change to the ClinicalTrials.gov interface build rather than the study record content.SummaryDifference0.0%

- Check49 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check56 days agoChange DetectedPublication added to the Publications section: Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis, Paediatr Drugs, 2026 Apr 2 (Online ahead of print).SummaryDifference0.0%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.